


CLAIMS

1. A compound of formula (I), or a salt thereof:



wherein:

R_1 is n -C₃₋₆alkyl or C₁₋₂alkoxyC₁₋₂alkyl-;

each R_2 independently represents halo, OH or C₁₋₃alkyl;

m is an integer having a value of 4, 5, 6 or 7;

n is an integer having a value of 0, 1, 2 or 3;

p is an integer having a value of 0, 1 or 2.

2. A compound according to claim 1, or a salt thereof, wherein R_1 is n -butyl.

3. A compound according to claim 1, or a salt thereof, wherein R_1 is 2-methoxyethyl.

4. A compound according to any of claims 1-3, or a salt thereof, wherein m is an integer having a value of 5 or 6.

5. A compound according to any of claims 1-4, or a salt thereof, wherein n is 1.

6. A compound according to any of claims 1-4, or a salt thereof, wherein n is 2.

7. A compound according to any of claims 1-6, or a salt thereof, wherein p is 0 or 1.


8. A compound according to any of claims 1-7, or a salt thereof, wherein each R_2 independently represents halo or OH.

9. A compound according to claim 8, or a salt thereof, wherein each R_2 independently represents F or OH.


10. A compound according to claim 1, or a salt thereof, selected from the group consisting of:

- 5-Butyl-3-(6-(piperidin-1-yl)hexyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine;
 5-(2-Methoxyethyl)-3-(6-(piperidin-1-yl)hexyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine;
 5-Butyl-3-(6-(pyrrolidin-1-yl)hexyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine;
 5-(2-Methoxyethyl)-3-(6-(pyrrolidin-1-yl)hexyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine;
 5-Butyl-3-(5-(piperidin-1-yl)pentyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine;
 5-Butyl-3-(5-(pyrrolidin-1-yl)pentyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine;
 5-Butyl-3-(7-(piperidin-1-yl)heptyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine;

- 5-Butyl-3-(7-(pyrrolidin-1-yl)heptyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine;
3-(6-(Azepan-1-yl)hexyl)-5-butyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine;
3-(5-(Azepan-1-yl)pentyl)-5-butyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine;
(*S*)-5-Butyl-3-(6-(3-fluoropyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine;
(*S*)-5-Butyl-3-(5-(3-fluoropyrrolidin-1-yl)pentyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine;
(*R*)-5-Butyl-3-(6-(3-fluoropyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine
formate;
(*R*)-5-Butyl-3-(5-(3-fluoropyrrolidin-1-yl)pentyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-
amine;
1-(6-(7-Amino-5-butyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-yl)hexyl)piperidin-4-ol;
1-(5-(7-Amino-5-butyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-yl)pentyl)piperidin-4-ol;
5-Butyl-3-(6-(4-fluoropiperidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine; and
5-Butyl-3-(5-(4-fluoropiperidin-1-yl)pentyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine.
11. A compound according to claim 1, or a salt thereof, which is 5-Butyl-3-(6-
(pyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine, of formula:



12. A compound according to any of claims 1-11, which is in the form of a
pharmaceutically acceptable salt.
13. A compound according to claim 12, selected from the group consisting of:
5-Butyl-3-(6-(pyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine maleate;
5-Butyl-3-(6-(pyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine dimaleate;
and
5-Butyl-3-(6-(pyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine hemi-
succinate.
14. A compound according to claim 12, which is 5-Butyl-3-(6-(pyrrolidin-1-yl)hexyl)-
1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine dimaleate, of formula:




15. A compound according to claim 14, which is in a crystalline solid state form characterised by an X-ray powder diffraction pattern having diffraction peaks at 2θ values of 5.3, 5.8, 6.4, 9.0, 10.1, 10.9, 11.6, 12.7, 16.0 and 19.1.
16. A compound according to any of claims 1-11, which is in the form of a free base.
17. A pharmaceutical composition comprising a compound as defined in any of claims 1-16, and one or more pharmaceutically acceptable excipients.
18. A vaccine composition comprising a compound as defined in any of claims 1-16, and an antigen or antigen composition.
19. A compound as defined in any of claims 1-16 for use in therapy.
20. A compound as defined in any of claims 1-16 for use in the treatment of allergic diseases and other inflammatory conditions, infectious diseases or cancer.
21. A compound as defined in any of claims 1-16 for use in the treatment of allergic rhinitis.
22. A compound as defined in any of claims 1-16 for use in the treatment of asthma.
23. Use of a compound as defined in any of claims 1-16 in the manufacture of a medicament for the treatment of allergic diseases and other inflammatory conditions, infectious diseases or cancer.
24. Use of a compound as defined in any of claims 1-16 in the manufacture of a medicament for the treatment of allergic rhinitis.
25. Use of a compound as defined in any of claims 1-16 in the manufacture of a medicament for the treatment of asthma.

26. A vaccine composition as defined in claim 18, for use in therapy.

27. Use of a vaccine composition as defined in claim 18 for the manufacture of a medicament for therapy.

CLAIMS

1. 5-Butyl-3-(6-(pyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine, of formula:



or a salt thereof.

2. A compound according to claim **1**, wherein the salt is a pharmaceutically acceptable salt.
3. A compound according to claim **2**, which is 5-Butyl-3-(6-(pyrrolidin-1-yl)hexyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-amine maleate.
4. A compound according to claim **1**, which is in the form of a free base.
5. A pharmaceutical composition comprising a compound as defined in claim **1** and one or more pharmaceutically acceptable excipients.
6. A pharmaceutical composition comprising a compound as defined in claim **3** and one or more pharmaceutically acceptable excipients.
7. A pharmaceutical composition comprising a compound as defined in claim **4** and one or more pharmaceutically acceptable excipients.